Hallett Timothy B, Gregson Simon, Dube Sabada, Garnett Geoff P
Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom.
PLoS Med. 2008 Mar 11;5(3):e53. doi: 10.1371/journal.pmed.0050053.
The roll-out of antiretroviral treatment (ART) in developing countries concentrates on finding patients currently in need, but over time many HIV-infected individuals will be identified who will require treatment in the future. We investigated the potential influence of alternative patient management and ART initiation strategies on the impact of ART programmes in sub-Saharan Africa.
We developed a stochastic mathematical model representing disease progression, diagnosis, clinical monitoring, and survival in a cohort of 1,000 hypothetical HIV-infected individuals in Africa. If individuals primarily enter ART programmes when symptomatic, the model predicts that only 25% will start treatment and, on average, 6 life-years will be saved per person treated. If individuals are recruited to programmes while still healthy and are frequently monitored, and CD4(+) cell counts are used to help decide when to initiate ART, three times as many are expected to be treated, and average life-years saved among those treated increases to 15. The impact of programmes can be improved further by performing a second CD4(+) cell count when the initial value is close to the threshold for starting treatment, maintaining high patient follow-up rates, and prioritising monitoring the oldest (> or = 35 y) and most immune-suppressed patients (CD4(+) cell count < or = 350). Initiating ART at higher CD4(+) cell counts than WHO recommends leads to more life-years saved, but disproportionately more years spent on ART.
The overall impact of ART programmes will be limited if rates of diagnosis are low and individuals enter care too late. Frequently monitoring individuals at all stages of HIV infection and using CD4 cell count information to determine when to start treatment can maximise the impact of ART.
在发展中国家推行抗逆转录病毒治疗(ART)主要集中于寻找当前有需求的患者,但随着时间推移,将会发现许多未来需要治疗的HIV感染者。我们调查了替代患者管理和ART启动策略对撒哈拉以南非洲地区ART项目影响的潜在作用。
我们建立了一个随机数学模型,用以表示非洲1000名假设的HIV感染者队列中的疾病进展、诊断、临床监测和生存情况。如果个体主要在出现症状时进入ART项目,该模型预测只有25%的人会开始治疗,且平均每位接受治疗的人可挽救6个生命年。如果个体在仍健康时被招募进项目并接受频繁监测,且使用CD4(+)细胞计数来帮助决定何时启动ART,预计接受治疗的人数将增加两倍,且接受治疗者的平均挽救生命年数增至15个。当初始值接近开始治疗的阈值时进行第二次CD4(+)细胞计数、保持较高的患者随访率以及优先监测年龄较大(≥35岁)和免疫抑制最严重(CD4(+)细胞计数≤350)的患者,可进一步提高项目的影响。在高于世界卫生组织推荐的CD4(+)细胞计数时启动ART可挽救更多生命年,但在ART上花费的年数会不成比例地增加。
如果诊断率低且个体就医过晚,ART项目的总体影响将受到限制。对HIV感染各个阶段的个体进行频繁监测,并利用CD4细胞计数信息来确定何时开始治疗,可使ART的影响最大化。